Ever since established in 2014, Sunland Fund is aimed to be one of the leading companies in the healthcare VC investment industry around the world. In August 2022, Sunland opens its overseas office, which marks its first step on global expansion.

Sunland’s overseas office is located in the heart of global healthcare innovation area: Massachusetts Route 128. Numerous prominent organizations are nearby, including top universities such as Harvard and MIT; famous healthcare research institutions such as Broad Institution and Massachusetts General Hospital; as well as world leading companies, such as Norvatis, Siemens, and Boston Scientific. By setting up its overseas office, Sunland takes first-mover advantages on connecting with top talents, innovative technologies, and investment opportunities.

Partnering with leading healthcare incubators and associations, Sunland has already merged into the global innovation community. Targeting the future development of China healthcare industry, Sunland’s overseas office will play more and more significant role on discovering and investing in the leading foreign startups. For one thing, we will strive to provide LPs with magnificent returns by investing in early-stage companies. For another, we will accelerate the growth of startups by helping entrepreneurs connect with various kinds of industrial resources.  

Sunland Fund’s founding partner, Dr. Daozhi Liu, comments about the meaning of overseas office: as a strategic investor, Sunland will keep leveraging its industrial resources and helping entrepreneurs and startups around the world. Sunland will focus on fulfilling unmet clinical needs by investing in innovative healthcare technologies and products. With deep understanding of full life-cycle of enterprises, we will strive to help global startups commercialize their technology, facilitate the whole regulatory approval process and eventually break into Chinese market.